Brief Intervention for Drug Abuse Using the WHO ASSIST

描述（由申请人提供）： 该提案描述了一项为期3年的研究，该研究将调查与酒精、吸烟和物质参与筛查测试（ASSIST）相关的高风险（非依赖性）非法药物使用的短期干预（BI）的有效性，ASSIST是世界卫生组织（WHO）开发的一种新工具。ASSIST最近由一个国际研究小组开发，用于筛查烟草、酒精、大麻、可卡因、安非他明、镇静剂、致幻剂、吸入剂、阿片类药物和其他药物的问题或危险使用。拟议的研究将允许美国参与一项国际多地点合作项目，以评估与WHO ASSIST相关的四种非法药物（大麻、苯丙胺、可卡因和阿片类药物）的短暂干预的有效性。该研究将采用随机对照设计，其中在大型牙科诊所接受治疗的合格患者（N=160名四种非法物质的非依赖性使用者）将被随机分配到实验条件或候补对照组。实验受试者将接受针对具有最高ASSIST严重性评分的药物的简短动机干预以及与该药物相关的自助材料。两组将在3个月和6个月时使用ASSIST和相关结局指标进行重新评估。该项目将在康涅狄格大学独立进行，但将与卫生组织在国际合作地点赞助的一项更大规模的多地点研究联系起来，该研究将再招募740名参与者。

DESCRIPTION (provided by applicant): This proposal describes a 3-year study that will investigate the effectiveness of a Brief Intervention (BI) for high risk (non-dependent) use of illicit drugs as linked to the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST), a new instrument developed by the World Health Organization (WHO). The ASSIST was recently developed by an international group of researchers to screen for problem or risky use of tobacco, alcohol, cannabis, cocaine, amphetamines, sedatives, hallucinogens, inhalants, opiates and other drugs. The proposed study will allow US participation in an international multi-site collaborative project to evaluate the effectiveness of a brief intervention for four illicit drugs (cannabis, amphetamines, cocaine and opiates) as linked to the WHO ASSIST. The study will use a randomized controlled design in which eligible patients (N=160 non-dependent users of four illicit substances) presenting for care at a large dental clinic will be randomly assigned to either an experimental condition or a waitlist control group. Experimental subjects will receive a brief motivational intervention for the drug with the highest ASSIST severity score as well as self-help materials relating to that drug. Both groups will be re-assessed at three and six months with the ASSIST and related outcome measures. The project will be conducted independently at the University of Connecticut but will be linked to a larger multi-site study being sponsored by WHO at collaborating international sites where an additional 740 participants will be recruited.